AACE Task Force for the Management of Dyslipidemia and Prevention of Atherosclerosis Writing Committee

被引：62

作者：

Jellinger, Paul S.

Smith, Donald A.

Mehta, Adi E.

Ganda, Om

Handelsman, Yehuda

Rodbard, Helena W.

Shepherd, Mark D.

Seibel, John A.

机构：

来源：

ENDOCRINE PRACTICE | 2012年 / 18卷 / 02期

关键词：

CORONARY-HEART-DISEASE; PRIMARY HYPERCHOLESTEROLEMIA; CARDIOVASCULAR-DISEASE; GEMFIBROZIL TREATMENT; METABOLIC SYNDROME; PLASMINOGEN-ACTIVATOR; MYOCARDIAL-INFARCTION; AMERICAN ASSOCIATION; DIABETES-MELLITUS; SERUM-CHOLESTEROL;

D O I：

10.4158/EP.18.2.269

中图分类号：

R5 [内科学];

学科分类号：

100201 [内科学];

摘要：

[No abstract available]

引用

页码：270 / 293

页数：24

共 100 条

[1]

Ciprofibrate versus gemfibrozil in the treatment of mixed hyperlipidemias:: An open-label, multicenter study [J].

Aguilar-Salinas, CA ;

Fanghänel-Salmón, G ;

Meza, E ;

Montes, J ;

Gulías-Herrero, A ;

Sánchez, L ;

Monterrubio-Flores, EA ;

González-Valdez, H ;

Pérez, FJG .

METABOLISM-CLINICAL AND EXPERIMENTAL, 2001, 50 (06) :729-733

[2]

Standards of Medical Care in Diabetes-2009 [J].

不详 .

DIABETES CARE, 2009, 32 :S13-S61

[3]

American Association of Clinical Endocrinologists Polycystic Ovary Syndrome Writing Committee, 2005, Endocr Pract, V11, P126

[4]

[Anonymous], 1992, Pediatrics, V89, P525

[5]

[Anonymous], 2011, LIV PIT

[6]

[Anonymous], 2004, 7 REP JOINT NAT COMM

[7]

[Anonymous], 2011, PRAV PRAV SOD

[8]

[Anonymous], 2006, COL COL HYDR

[9]

[Anonymous], 2008, LOP GEMF

[10]

[Anonymous], 2010, MEV

← 1 2 3 4 5 6 7 8 9 10 →